Get the Stockscreener App
3.04
2.01%
0.06
Heartsciences Inc stock is traded at $3.04, with a volume of 17,779.
It is up +2.01% in the last 24 hours and up +13.86% over the past month.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
See More
Previous Close:
$2.98
Open:
$2.98
24h Volume:
17,779
Relative Volume:
0.40
Market Cap:
$9.85M
Revenue:
-
Net Income/Loss:
$-7.29M
P/E Ratio:
-0.1248
EPS:
-24.3686
Net Cash Flow:
$-6.81M
1W Performance:
-1.62%
1M Performance:
+13.86%
6M Performance:
-19.79%
1Y Performance:
-14.88%
1-Day Range:
$2.96
$3.0999
1-Week Range:
$2.96
$3.21
52-Week Range:
$2.01
$6.47
Heartsciences Inc Stock (HSCS) Company Profile
Name
Heartsciences Inc
Sector
Industry
Phone
682-237-7781
Address
550 RESERVE ST, SUITE 360, SOUTHLAKE
Compare HSCS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSCS
Heartsciences Inc
|
3.0999 | 9.47M | 0 | -7.29M | -6.81M | -24.37 |
|
ABT
Abbott Laboratories
|
127.03 | 222.19B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.64 | 144.97B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.64 | 140.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.78 | 128.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.58 | 49.82B | 5.88B | 1.34B | 799.60M | 2.3489 |
Heartsciences Inc Stock (HSCS) Latest News
Is HeartSciences Inc. Equity Warrant stock supported by strong cash flows2026 world cup usa national team group stage defensive leaders transition play odds analysis expert opinion - ulpravda.ru
What analysts say about HeartSciences Inc Equity Warrant stockMarket Depth Overview & Free Technical Analysis and Insights - earlytimes.in
Market Meltdown the Virus and our ActionablesStock Price Divergence & Affordable Trading Strategies - bollywoodhelpline.com
Indo Count Industries Limited (ICIL) Expands into New MarketPrice-to-Book Ratio Updates & Exceptional Capital Growth - bollywoodhelpline.com
HeartSciences (NASDAQ:HSCS) Price Target Raised to $9.20 at Ascendiant Capital Markets - Defense World
HeartSciences (NASDAQ:HSCS) and Movano (NASDAQ:MOVE) Critical Survey - Defense World
Why HeartSciences Inc. Equity Warrant stock remains resilient2025 Momentum Check & AI Forecasted Stock Moves - DonanımHaber
Ascendiant Capital Maintains HeartSciences (HSCS) Buy Recommendation - Nasdaq
HeartSciences (HSCS) Receives Updated Analyst Rating and Price T - GuruFocus
Is HeartSciences Inc. Equity Warrant stock a top pick in earnings seasonMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
HeartSciences (NASDAQ:HSCS) & Health Catalyst (NASDAQ:HCAT) Critical Analysis - Defense World
Does HeartSciences Inc. stock trade at a discount to peersJuly 2025 Spike Watch & Verified Swing Trading Watchlists - Улправда
Why HeartSciences Inc. Equity Warrant stock could see breakout soon2025 Sector Review & Fast Entry High Yield Tips - Улправда
Is HeartSciences Inc. stock a safe haven assetQuarterly Market Review & Comprehensive Market Scan Insights - Bölüm Sonu Canavarı
Will HeartSciences Inc. Equity Warrant stock attract ESG investorsMarket Weekly Review & Long Hold Capital Preservation Plans - Улправда
Will HeartSciences Inc. Equity Warrant stock recover faster than peersJuly 2025 Final Week & Growth Focused Stock Pick Reports - DonanımHaber
Will HeartSciences Inc. Equity Warrant stock deliver shareholder valueJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - Улправда
History Review: Does HeartSciences Inc. stock trade at a discount to peers2025 Major Catalysts & Real-Time Volume Triggers - Улправда
HeartSciences Submits MyoVista wavECG Device for FDA Clearance - Diagnostic and Interventional Cardiology
HeartSciences approves indemnification agreements for directors and officers By Investing.com - Investing.com Nigeria
HeartSciences approves indemnification agreements for directors and officers - Investing.com
Heart Test Laboratories Approves Indemnification Agreement - TipRanks
HeartSciences reports no meaningful revenue in Q2 2026 - Medical Buyer
HeartSciences Inc. Reports Second Quarter Fiscal 2026 Financial Results and Progress on MyoVista Insights and wavECG Device Submissions - Quiver Quantitative
HeartSciences (Nasdaq: HSCS) Q2 shows $2M cash, MyoVista Insights push - Stock Titan
HeartSciences (NASDAQ: HSCS) posts loss, highlights going concern and new funding - Stock Titan
HeartSciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2025 - marketscreener.com
HeartSciences files FDA 510(k) for MyoVista WaveCG device - marketscreener.com
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device - The Manila Times
HeartSciences (Nasdaq: HSCS) separates device, AI-ECG FDA paths - Stock Titan
HeartSciences Inc. Announces Commercial Release of MyoVista Insights™ Version 1.1 Enhancing ECG System Capabilities - Quiver Quantitative
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with ... - Enidnews.com
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1 - The Manila Times
HeartSciences Announces Major Upgrade to User Features of - GlobeNewswire
Gross profit of HeartSciences Inc. from 2021 to 2024 - Statista
HeartSciences (HSCS) to Release Quarterly Earnings on Monday - Defense World
Reviewing Hims & Hers Health (NYSE:HIMS) and HeartSciences (NASDAQ:HSCS) - Defense World
S&P 500, NASDAQ and Dow continue upward trend as Wall Street rises to the edge of its all-time high; Treas - The Economic Times
Risk Off: Why MLPR stock is seen as undervaluedPrice Action & Expert-Curated Trade Recommendations - BỘ NỘI VỤ
How HeartSciences Inc. Equity Warrant stock performs in rate cut cyclesJuly 2025 Levels & Weekly Return Optimization Alerts - Newser
HeartSciences (HSCSW) Stock Analysis Report | Financials & Insights - Benzinga
Will HeartSciences Inc. Equity Warrant stock keep outperforming rivalsJuly 2025 Momentum & Reliable Intraday Trade Alerts - Newser
How HeartSciences Inc. stock performs after earningsJuly 2025 Analyst Calls & Low Risk High Reward Ideas - Newser
HeartSciences (HSCS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
CapEx per share of HeartSciences Inc. Warrant 2022- on Heart Test Lab Rg – NASDAQ:HSCSW - TradingView
HeartSciences (NASDAQ:HSCS) and Tempus AI (NASDAQ:TEM) Financial Survey - Defense World
HeartSciences (HSCS) Stock Price, Quote, News & History - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Why HeartSciences Inc. stock is a must watch in 2025Quarterly Market Review & Daily Price Action Insights - newser.com
Why HeartSciences Inc. stock is favored by pension fundsTrade Risk Assessment & Long-Term Safe Return Strategies - newser.com
Heartsciences Inc Stock (HSCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):